Merck, a leading science and technology company, has expanded its manufacturing facility in Jigani, Bengaluru, strengthening local production of critical chemistry and biology materials for India’s growing life science sector and customers across the Asia-Pacific region.
“India is emerging as an increasingly important hub for life science innovation and manufacturing,” said Dhananjay Singh, Managing Director, Life Science business of Merck, India. “Merck is investing about €13 million in its Jigani site to strengthen regional manufacturing and expand biology and chemistry capabilities across India and the Asia-Pacific region. This investment will reinforce our global supply chain and support the ‘Make in India’ initiative. We appreciate the continued collaboration from DPIIT, the Heavy Water Board, the Government of Karnataka, and Invest India as Merck expands Jigani.”
The expansion will add biological buffer manufacturing to the site’s established chemistry capabilities, providing customers in research, diagnostics, biotechnology, and biopharmaceutical manufacturing with an integrated offering. By supporting customers from research and development through scale-up, commercial production, the expanded facility will help advance India’s strategic role in global life science innovation.
The facility reserves 34% of its site area for greenbelt, including trees and vegetation that help support environmental protection and sustainable operations.
The Jigani site will manufacture biological buffers and raw materials for diagnostic applications used in DNA research, cell culture, diagnostics, and drug manufacturing. These materials will be produced locally under temperature-controlled conditions. This will help to improve supply reliability, reduce import dependence, and enable faster responses to customer’s scientific and manufacturing needs, as well as reinforces Merck’s in-region, for-region approach to strengthening supply and access across key markets.